TERNS PHARMACEUTICALS INC (TERN) Stock Analyst Earnings Estimates
NASDAQ:TERN - Nasdaq - US8808811074 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1M | -100.00% | 13.056M | 17.238M 32.03% | 125.31M 626.94% | 214.2M 70.94% | 458.52M 114.06% | ||||||||
| EBITDA YoY % growth | -70M -280.64% | -36.64M 47.66% | -49.35M -34.69% | -64.25M -24.72% | -104.478M -65.19% | -105.06M 0.69% | -118.258M -17.12% | -135.268M -14.38% | -149.791M -10.74% | -118.116M 21.15% | -95.778M 18.91% | 125.97M 231.52% | 166.97M 32.55% | 514.39M 208.07% | |
| EBIT YoY % growth | -70.2M -280.28% | -37.03M 47.25% | -49.86M -34.65% | -64.802M -24.41% | -135.246M -65.34% | -105.442M 0.67% | -120.558M -18.34% | -136.63M -13.33% | -153.585M -12.41% | -165.386M -7.68% | -149.95M 9.33% | -30.607M 79.59% | 49.066M 260.31% | 279.72M 470.09% | |
| Operating Margin | N/A | N/A | -4,986.00% | N/A | N/A | N/A | N/A | N/A | N/A | -1,266.74% | -869.88% | -24.43% | 22.91% | 61.00% | |
| EPS YoY % growth | N/A | N/A | -2.34 28.53% | -1.92 21.79% | -1.36 30.60% | -1.23 11.02% | -1.20 -6.02% | -1.36 -13.29% | -1.57 -16.03% | -1.42 9.97% | -0.86 39.21% | -0.13 84.62% | 0.49 469.23% | 1.53 212.50% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | |
|---|---|---|---|
| EPS Q2Q % growth | -0.30 -7.33% | -0.31 -27.13% | -0.31 -20.05% |
| Revenue Q2Q % growth | |||
| EBITDA Q2Q % growth | -33.66M -38.40% | -35.7M -42.50% | N/A |
| EBIT Q2Q % growth | -30.117M -20.47% | -31.614M -21.83% | -32.354M -17.97% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -0.26 16.13% | -0.30 | 0.04 | 12.10% |
| Q1 2025 Q2Q % growth | -0.26 13.33% | -0.29 | 0.03 | 8.96% |
| Q4 2024 Q2Q % growth | -0.24 17.24% | -0.32 | 0.08 | 24.07% |
| Q3 2024 Q2Q % growth | -0.28 33.33% | -0.33 | 0.05 | 14.33% |
| Q2 2024 Q2Q % growth | -0.31 -24.00% | -0.35 | 0.04 | 10.61% |
| Q1 2024 Q2Q % growth | -0.30 3.23% | -0.34 | 0.04 | 12.85% |
| Q4 2023 Q2Q % growth | -0.29 | -0.30 | 0.01 | 2.71% |
| Q3 2023 Q2Q % growth | -0.42 4.55% | -0.31 | -0.11 | -34.76% |
| Q2 2023 Q2Q % growth | -0.25 54.55% | -0.35 | 0.10 | 27.68% |
| Q1 2023 Q2Q % growth | -0.31 43.64% | -0.27 | -0.04 | -13.53% |
| Q4 2022 Q2Q % growth | -0.29 48.21% | -0.44 | 0.15 | 33.88% |
| Q3 2022 Q2Q % growth | -0.44 6.38% | -0.53 | 0.09 | 17.04% |
| Q2 2022 Q2Q % growth | -0.55 -27.91% | -0.61 | 0.06 | 9.12% |
| Q1 2022 Q2Q % growth | -0.55 37.50% | -0.66 | 0.11 | 16.18% |
| Q4 2021 Q2Q % growth | -0.56 98.19% | -0.64 | 0.08 | 12.39% |
| Q3 2021 Q2Q % growth | -0.47 | -0.62 | 0.15 | 23.63% |
| Q2 2021 Q2Q % growth | -0.43 | -0.72 | 0.29 | 40.62% |
| Q1 2021 Q2Q % growth | -0.88 | -0.79 | -0.09 | -11.56% |
| Q4 2020 Q2Q % growth | -30.94 | -0.93 | -30.01 | -3,233.33% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2022 Q2Q % growth | -100.00% | % |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 2.72% | 13.6% | 0% | 5.4% |
| Revenue | N/A | N/A | N/A | N/A |